GC012F, CAR-T Cell Therapy Candidate, Granted FDA Orphan Drug Status

Gracell Biotechnologies’ investigational new treatment for multiple myeloma, GC012F, has been named an orphan drug by the U.S. Food and Drug Administration (FDA).

Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership

A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including…